You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Merck
AstraZeneca
McKinsey
Colorcon

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR COMETRIQ

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Cometriq

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01703065 Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer Recruiting National Cancer Institute (NCI) N/A 2013-09-01 This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01703065 Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer Recruiting Prostate Cancer Foundation N/A 2013-09-01 This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01703065 Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer Recruiting University of Washington N/A 2013-09-01 This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01709435 Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Active, not recruiting National Cancer Institute (NCI) Phase 1 2012-11-01 This phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01716715 Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Active, not recruiting National Cancer Institute (NCI) Phase 2 2012-11-01 This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether cabozantinib-s-malate or paclitaxel is more effective at treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer.
NCT01811212 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Suspended Exelixis Phase 2 2013-05-01 This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor.
NCT01811212 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Suspended National Cancer Institute (NCI) Phase 2 2013-05-01 This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cometriq

Condition Name

Condition Name for Cometriq
Intervention Trials
Recurrent Ovarian Carcinoma 3
Stage IV Renal Cell Cancer AJCC v8 3
Recurrent Renal Cell Carcinoma 3
Clear Cell Renal Cell Carcinoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cometriq
Intervention Trials
Carcinoma 22
Carcinoma, Renal Cell 8
Neoplasms 7
Thyroid Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cometriq

Trials by Country

Trials by Country for Cometriq
Location Trials
United States 292
Canada 9
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cometriq
Location Trials
California 14
Pennsylvania 12
Washington 11
Massachusetts 11
Ohio 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cometriq

Clinical Trial Phase

Clinical Trial Phase for Cometriq
Clinical Trial Phase Trials
Phase 3 1
Phase 2 26
Phase 1/Phase 2 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cometriq
Clinical Trial Phase Trials
Not yet recruiting 15
Active, not recruiting 9
Recruiting 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cometriq

Sponsor Name

Sponsor Name for Cometriq
Sponsor Trials
National Cancer Institute (NCI) 25
Exelixis 10
University of Washington 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cometriq
Sponsor Trials
NIH 25
Other 15
Industry 12
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKinsey
Harvard Business School
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.